Kukje Pharma Co., Ltd. (KRX:002720)
South Korea
· Delayed Price · Currency is KRW 4,650.00
-15.00 (-0.32%)
Last updated: Mar 25, 2025
Kukje Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 156,463 | 135,373 | 126,583 | 119,746 | 130,395 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 156,463 | 135,373 | 126,583 | 119,746 | 130,395 | Upgrade
|
| Revenue Growth (YoY) | 15.58% | 6.94% | 5.71% | -8.17% | 17.34% | Upgrade
|
| Cost of Revenue | 73,968 | 68,148 | 63,329 | 65,275 | 65,590 | Upgrade
|
| Gross Profit | 82,495 | 67,225 | 63,254 | 54,470 | 64,805 | Upgrade
|
| Selling, General & Admin | 72,895 | 66,699 | 56,119 | 53,538 | 49,234 | Upgrade
|
| Research & Development | 1,811 | 2,646 | 1,967 | 2,772 | 3,037 | Upgrade
|
| Operating Expenses | 75,793 | 69,214 | 57,982 | 56,146 | 58,763 | Upgrade
|
| Operating Income | 6,702 | -1,989 | 5,273 | -1,676 | 6,041 | Upgrade
|
| Interest Expense | -1,206 | -1,440 | -1,000 | -696.43 | -650.13 | Upgrade
|
| Interest & Investment Income | 428.67 | 394.02 | 230.88 | 114.3 | 139.41 | Upgrade
|
| Earnings From Equity Investments | - | - | 23.21 | -72.91 | -13.43 | Upgrade
|
| Currency Exchange Gain (Loss) | 303.91 | 163.51 | 450.12 | 589.96 | -688.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 492.72 | -2,254 | 270.73 | 627.72 | 340.29 | Upgrade
|
| EBT Excluding Unusual Items | 6,721 | -5,126 | 5,247 | -1,113 | 5,169 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.59 | 22.11 | - | - | 26.38 | Upgrade
|
| Gain (Loss) on Sale of Assets | 114.27 | 290.39 | 13.93 | 31.51 | 366.75 | Upgrade
|
| Asset Writedown | -226.64 | -1,867 | -515.82 | -28.5 | 31.68 | Upgrade
|
| Pretax Income | 6,609 | -6,681 | 4,745 | -1,110 | 5,594 | Upgrade
|
| Income Tax Expense | 1,403 | 1,734 | 1,202 | 445.53 | 3,399 | Upgrade
|
| Earnings From Continuing Operations | 5,206 | -8,415 | 3,543 | -1,556 | 2,195 | Upgrade
|
| Minority Interest in Earnings | -0.9 | -0.3 | 14.56 | -3.34 | 8.43 | Upgrade
|
| Net Income | 5,205 | -8,415 | 3,557 | -1,559 | 2,203 | Upgrade
|
| Net Income to Common | 5,205 | -8,415 | 3,557 | -1,559 | 2,203 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Change (YoY) | 0.27% | 0.09% | -0.03% | -0.03% | -0.00% | Upgrade
|
| EPS (Basic) | 256.00 | -415.00 | 175.58 | -76.93 | 108.67 | Upgrade
|
| EPS (Diluted) | 256.00 | -415.00 | 175.58 | -77.14 | 108.67 | Upgrade
|
| Free Cash Flow | 1,029 | 2,529 | 5,245 | 7,705 | -6,500 | Upgrade
|
| Free Cash Flow Per Share | 50.60 | 124.73 | 258.88 | 380.18 | -320.63 | Upgrade
|
| Gross Margin | 52.73% | 49.66% | 49.97% | 45.49% | 49.70% | Upgrade
|
| Operating Margin | 4.28% | -1.47% | 4.17% | -1.40% | 4.63% | Upgrade
|
| Profit Margin | 3.33% | -6.22% | 2.81% | -1.30% | 1.69% | Upgrade
|
| Free Cash Flow Margin | 0.66% | 1.87% | 4.14% | 6.43% | -4.98% | Upgrade
|
| EBITDA | 9,904 | 2,215 | 9,760 | 2,743 | 9,667 | Upgrade
|
| EBITDA Margin | 6.33% | 1.64% | 7.71% | 2.29% | 7.41% | Upgrade
|
| D&A For EBITDA | 3,203 | 4,204 | 4,488 | 4,419 | 3,626 | Upgrade
|
| EBIT | 6,702 | -1,989 | 5,273 | -1,676 | 6,041 | Upgrade
|
| EBIT Margin | 4.28% | -1.47% | 4.17% | -1.40% | 4.63% | Upgrade
|
| Effective Tax Rate | 21.23% | - | 25.34% | - | 60.77% | Upgrade
|
| Advertising Expenses | 3,692 | 6,015 | 7,504 | 7,250 | 6,300 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.